Group One Trading, L.P. Mirati Therapeutics, Inc. Transaction History

Group One Trading, L.P.

$3.01 Billion
Q2 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $15.8 Million - $23.4 Million	375,408 Added 969.9%	414,114 $24.3 Million
Q3 2023 Nov 09, 2023	BUY	$27.8 - $45.35 $73,892 - $120,540	2,658 Added 7.37%	38,706 $1.69 Million
Q2 2023 Aug 09, 2023	BUY	$36.13 - $49.49 $684,229 - $937,241	18,938 Added 110.68%	36,048 $1.3 Million
Q1 2023 May 12, 2023	SELL	$36.54 - $54.26 $831,650 - $1.23 Million	-22,760 Reduced 57.09%	17,110 $636,000
Q4 2022 Feb 09, 2023	SELL	$41.27 - $98.62 $1.31 Million - $3.13 Million	-31,713 Reduced 44.3%	39,870 $1.81 Million
Q3 2022 Nov 09, 2022	SELL	$59.5 - $86.7 $208,012 - $303,103	-3,496 Reduced 4.66%	71,583 $5 Million
Q2 2022 Aug 11, 2022	BUY	$39.16 - $88.71 $1.51 Million - $3.42 Million	38,576 Added 105.68%	75,079 $5.04 Million
Q1 2022 May 12, 2022	BUY	$75.82 - $150.97 $2.47 Million - $4.91 Million	32,514 Added 815.09%	36,503 $3 Million
Q4 2021 Feb 11, 2022	BUY	$132.01 - $190.29 $526,587 - $759,066	3,989 New	3,989 $585,000
Q2 2019 Aug 09, 2019	SELL	$59.49 - $104.71 $812,157 - $1.43 Million	-13,652 Closed	0 $0
Q1 2019 May 13, 2019	BUY	$43.65 - $78.95 $417,119 - $754,446	9,556 Added 233.3%	13,652 $1 Million
Q4 2018 Feb 06, 2019	BUY	$32.0 - $47.43 $66,112 - $97,990	2,066 Added 101.77%	4,096 $174,000
Q3 2018 Nov 08, 2018	BUY	$47.1 - $62.7 $95,613 - $127,281	2,030 New	2,030 $96,000
Q2 2018 Aug 14, 2018	SELL	$26.05 - $52.4 $119,022 - $239,415	-4,569 Closed	0 $0
Q1 2018 May 11, 2018	BUY	$17.2 - $34.95 $78,586 - $159,686	4,569 New	4,569 $140,000
Q4 2017 Feb 09, 2018	SELL	$12.65 - $19.0 $60,201 - $90,421	-4,759 Closed	0 $0
Q3 2017 Nov 15, 2017	BUY	$4.7 - $11.7 $7,797 - $19,410	1,659 Added 53.52%	4,759 $56,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,100	3,100 $11,000

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Group One Trading, L.P., based on Form 13F filings with the SEC.

News

Stay updated on Group One Trading, L.P. with notifications on news.

Account